[
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of acute pancreatitis (AP) 0-90 days prior to enrollment date\n* Participant fully understands and is able to participate in all aspects of the study, including providing informed consent, completion of case report forms (CRFs), telephone interviews, metabolic testing, and planned longitudinal follow-ups\n\nExclusion Criteria:\n\n* Diagnosis of definite chronic pancreatitis (CP) at enrollment based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic resonance Imaging (MRI) or Magnetic Resonance Cholangiopancreatography (MRCP): (a) Parenchymal or ductal calcifications on CT scan (after excluding the possibility that calcifications are vascular); (b) Intraductal filling defects suggestive of calcifications on MRI and/or MRCP\n* Potential participants with post-endoscopic retrograde cholangiopancreatography (post- ERCP) AP who are hospitalized for \\<48 hours.\n* Prior (i.e., before enrollment) direct endoscopic necrosectomy of the pancreas or percutaneous necrosectomy or drainage of necrotic collection(s). Participants who require this during follow-up will remain in the study\n* Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and metastasis\n* Confirmed or suspected cystic tumor associated with main pancreatic duct dilation, or believed to be the cause of AP (in the site-PI's judgement)\n* Prior pancreatic surgery, including, but not limited to: distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, Frey procedure\n* Use of disallowed concomitant medications within 30 days prior to enrollment. A comprehensive list of disallowed medications will be included and routinely updated in the study's Manual of Procedures\n* Severe systemic illness that in the judgement of the investigative team will confound outcome assessments of DM and immunological outcomes or pose additional risk for harms, including: history of solid organ transplant, acquired immunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanoma skin cancer) within 12 months prior to enrollment, chronic kidney disease with estimate glomerular filtration rate (eGFR) \\< 30 or on dialysis prior to AP, and cirrhosis (based on imaging or biopsy), or any other medical condition that in the opinion of the site-PI carries a life expectancy of \\<12 months.\n* Known pregnancy at the time of enrollment. Participants who become pregnant during follow-up will remain in the study, but may have modified study assessments for safety\n* Incarceration\n* Any other condition or factor that would compromise the participant's safety or the scientific integrity of the study",
        "InclusionCriteria": "* Diagnosis of acute pancreatitis (AP) 0-90 days prior to enrollment date\n* Participant fully understands and is able to participate in all aspects of the study, including providing informed consent, completion of case report forms (CRFs), telephone interviews, metabolic testing, and planned longitudinal follow-ups",
        "ExclusionCriteria": "* Diagnosis of definite chronic pancreatitis (CP) at enrollment based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic resonance Imaging (MRI) or Magnetic Resonance Cholangiopancreatography (MRCP): (a) Parenchymal or ductal calcifications on CT scan (after excluding the possibility that calcifications are vascular); (b) Intraductal filling defects suggestive of calcifications on MRI and/or MRCP\n* Potential participants with post-endoscopic retrograde cholangiopancreatography (post- ERCP) AP who are hospitalized for \\<48 hours.\n* Prior (i.e., before enrollment) direct endoscopic necrosectomy of the pancreas or percutaneous necrosectomy or drainage of necrotic collection(s). Participants who require this during follow-up will remain in the study\n* Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and metastasis\n* Confirmed or suspected cystic tumor associated with main pancreatic duct dilation, or believed to be the cause of AP (in the site-PI's judgement)\n* Prior pancreatic surgery, including, but not limited to: distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, Frey procedure\n* Use of disallowed concomitant medications within 30 days prior to enrollment. A comprehensive list of disallowed medications will be included and routinely updated in the study's Manual of Procedures\n* Severe systemic illness that in the judgement of the investigative team will confound outcome assessments of DM and immunological outcomes or pose additional risk for harms, including: history of solid organ transplant, acquired immunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanoma skin cancer) within 12 months prior to enrollment, chronic kidney disease with estimate glomerular filtration rate (eGFR) \\< 30 or on dialysis prior to AP, and cirrhosis (based on imaging or biopsy), or any other medical condition that in the opinion of the site-PI carries a life expectancy of \\<12 months.\n* Known pregnancy at the time of enrollment. Participants who become pregnant during follow-up will remain in the study, but may have modified study assessments for safety\n* Incarceration\n* Any other condition or factor that would compromise the participant's safety or the scientific integrity of the study",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "18 Years",
        "NCTId": "NCT05197920",
        "startDate": "2022-01-14",
        "completionDate": "2025-04-30",
        "durationDays": 1202,
        "daysUntilEnd": 264
    },
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n* Individuals 2.5 to 45 years old who have an immediate family member with type 1 diabetes (such as a child, parent, or sibling)\n* Individuals 2.5-20 years old who have an extended family member with type 1 diabetes (such as a cousin, niece, nephew, aunt, uncle, grandparent, or half-sibling)\n* Individuals 2.5-45 years old without a type 1 diabetes proband, who are known to have 1 or more islet antibody are eligible for screening if needed to determine eligibility for a clinical trial to delay or prevent disease progression.\n\nExclusion Criteria:\n\nTo be eligible a person must not:\n\n* Have diabetes already\n* Have a previous history of being treated with insulin or oral diabetes medications.\n* Currently be using systemic immunosuppressive agents (topical and inhaled agents are acceptable)\n* Have any known serious diseases",
        "InclusionCriteria": "* Individuals 2.5 to 45 years old who have an immediate family member with type 1 diabetes (such as a child, parent, or sibling)\n* Individuals 2.5-20 years old who have an extended family member with type 1 diabetes (such as a cousin, niece, nephew, aunt, uncle, grandparent, or half-sibling)\n* Individuals 2.5-45 years old without a type 1 diabetes proband, who are known to have 1 or more islet antibody are eligible for screening if needed to determine eligibility for a clinical trial to delay or prevent disease progression.",
        "ExclusionCriteria": "To be eligible a person must not:\n\n* Have diabetes already\n* Have a previous history of being treated with insulin or oral diabetes medications.\n* Currently be using systemic immunosuppressive agents (topical and inhaled agents are acceptable)\n* Have any known serious diseases",
        "HealthyVolunteers": true,
        "Gender": "ALL",
        "MinimumAge": "30 Months",
        "NCTId": "NCT00097292",
        "startDate": "2004-02",
        "completionDate": "2025-07",
        "durationDays": 7821,
        "daysUntilEnd": 326
    },
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n1. Provide informed consent or assent as appropriate and, if \\< 18 years of age have a parent or legal guardian provide informed consent\n2. Age 12-35 years (both inclusive) at the time of signing informed consent and assent\n3. Diagnosis of T1D within 100 days of the baseline visit (V0).\n4. Positive for at least one islet cell autoantibody; Glutamate decarboxylase (GAD)65A, mIAA (if obtained within 10 days of the onset of insulin therapy), IA-2A, ICA, or ZnT8A\n5. Stimulated C-peptide of \u22650.2 pmol/mL measured during mixed-meal tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes\n6. HbA1c \u2264 10 %\n7. Body weight \u2265 35kg at screening\n8. Willing to comply with intensive diabetes management and wear a Continuous Glucose Monitoring Device (CGM)\n9. Participants who are Cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) seronegative at screening must be CMV and/or EBV Polymerase chain reaction (PCR) negative within 30 days of randomization and may not have had signs or symptoms of a CMV and/or EBV-compatible illness lasting longer than 7 days within 30 days of the baseline visit (V0).\n10. Participants who are CMV and/or EBV seropositive at screening must be CMV PCR negative and/or EBV PCR \\<2,000 IU/mL and must have no signs or symptoms of acute infection at the time of the baseline visit (V0).\n11. Be up to date on recommended vaccinations based on age of participants\\*\n12. Participants are required to receive killed influenza vaccination at least 2 weeks prior to the baseline visit (V0) when vaccine for the current or upcoming flu season is available.\n\n    Enrollment must be delayed at least 4 weeks from administration of a killed vaccine other than influenza and COVID-19 and 6 weeks from a live vaccination. Live vaccinations and non-live vaccinations (other than influzena and COVID-19) should not be given while on study drug and be postponed at least 3 months after the last dose of study drug.\n13. If participant is female with reproductive potential, she must have a negative pregnancy test at screening and be willing to avoid pregnancy using a highly-effective contraceptive method for the duration of the study\n14. Males of reproductive age must use a highly-effective contraceptive method during the treatment phase and for 3 months following last dose of study drug\n\n    * For COVID-19 vaccination, all participants will be strongly encouraged to be up-to-date with COVID-19 vaccine (s) as indicated by country-specific guidelines at least 2 weeks prior to the baseline visit (V0).\n\nExclusion Criteria:\n\n1. Current or ongoing use of non-insulin pharmaceuticals or medication that affect glycemic control or glucose homeostasis within 7 days prior to screening or any prohibited concomitant medication listed in section 4.8\n2. Untreated hypothyroidism or active Graves' disease\n3. Concurrent treatment with other immunosuppressive agents (including biologics or steroids), other than inhaled or topical glucocorticoids\n4. Active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 1 month prior to Day 0 or superficial skin infection within 1 week prior to Day 0\n5. Active acute or chronic infection requiring treatment with intravenous therapy (IV) within a minimum 1 month prior to Day 0\n\n   a. Specific cases should be reviewed by Infectious Disease Committee prior to enrollment\n6. Have active signs or symptoms of acute infection at the time of the baseline visit (V0).\n7. Significant trauma or major surgery within 1 month of signing informed consent.\n8. Considered in imminent need for surgery or with elective surgery scheduled to occur during the study\n9. History of disseminated herpes zoster or disseminated herpes simplex or a recurrent (more than one episode of) localized, dermatomal herpes zoster\n10. Have evidence of prior or current tuberculosis infection as assessed by Purified Protein Derivative (PPD), interferon gamma release assay (IGRA) or by history\n11. Have evidence of current or past HIV or Hepatitis B infection\n12. Have evidence of active Hepatitis C infection\n13. Have current, confirmed COVID-19 infection\n14. Current or history of Deep vein thrombosis (DVT), Pulmonary embolism (PE), or other thromboembolic events or history of inherited coagulopathies\n15. First degree relative with a history of unprovoked venous thromboembolism (i.e. without known underlying cause such as trauma, surgery, immobilization, prolonged travel, pregnancy, hormone use, or plaster cast), which suggests that a participant may be at increased risk of inherited coagulation disorder\n16. Any present malignancies or history of malignancy, other than a successfully treated nonmelanoma skin cancer\n17. History of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease\n18. Known or suspected polymorphism in the Cytochrome P450 2C19 (CYP2C19 gene, resulting in classification as a poor CYP2C19 metabolizer).\n19. Have renal impairment (eGFR\\< 60 mL/min)\n20. Currently on anti-platelet therapies, excluding low dose aspirin\n21. One or more screening laboratory values as stated\n\n    1. Neutrophils \\< 1,500 /\u03bcL\n    2. Lymphocytes \\< 800 /\u03bcL\n    3. Platelets \\< 150,000 / \u03bcL\n    4. Hemoglobin \\< 6.2 mmol/L (10.0 g/dL)\n    5. Potassium \\> 5.5 mmol/L or \\<3.0 mmol/L\n    6. Sodium \\> 150mmol/L or \\< 130mmol/L\n    7. AST or ALT \u2265 2.5 times the upper limit of normal\n    8. Bilirubin \u2265 1.5 times upper limit of normal unless diagnosed with Gilbert's syndrome\n    9. LDL \\>160 mg/dL\n22. Vaccination with a live virus within the last 6 weeks and killed vaccine within 4 weeks (except 2 weeks for flu vaccine and COVID vaccine)\n23. Be currently pregnant or lactating or anticipate becoming pregnant during the study\n24. Male participants able to father children and female participants of childbearing potential who are unwilling or unable to use 2 effective methods (at least 1 highly effective method) of contraception, including abstinence, as outlined in this protocol for the duration of the study and for at least 3 months after the last dose of investigational product\n25. Be currently participating in another T1D treatment study\n26. Have hearing loss with progression over the previous 5 years, or sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered acute, fluctuating, or progressive\n27. Acute coronary syndrome (e.g., myocardial infarction, unstable angina pectoris) and any history of cerebrovascular disease within 24 weeks before screening; Heart failure NYHA (New York Heart Association) III, NYHA IV\n28. ANY of the following conditions at screening:\n\n    a. Screening 12-lead electrocardiogram (ECG) that demonstrates: i. Clinically significant abnormalities requiring treatment (eg, acute myocardial infarction, serious tachy- or brady-arrhythmias) or indicating serious underlying heart disease (eg, cardiomyopathy, Wolff-Parkinson- White syndrome); ii. Confirmed QT corrected using Fridericia's correction factor (QTcF) prolongation (\\>450 milliseconds).\n\n    b. Long QT Syndrome, a family history of Long QT Syndrome, or a history of Torsades de Pointes (TdP).\n29. History of chronic alcohol abuse or intravenous drug abuse or other illicit drug abuse within 2 years prior to screening\n30. Current or past use of tobacco or nicotine containing products more than the equivalent of 5 cigarettes per day\n31. Participant is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the trial\n32. Have any complicating medical issues or abnormal clinical laboratory results that may interfere with study conduct, or cause increased risk\n33. Any condition that in the investigator's opinion may adversely affect study participation or may compromise the study results",
        "InclusionCriteria": "1. Provide informed consent or assent as appropriate and, if \\< 18 years of age have a parent or legal guardian provide informed consent\n2. Age 12-35 years (both inclusive) at the time of signing informed consent and assent\n3. Diagnosis of T1D within 100 days of the baseline visit (V0).\n4. Positive for at least one islet cell autoantibody; Glutamate decarboxylase (GAD)65A, mIAA (if obtained within 10 days of the onset of insulin therapy), IA-2A, ICA, or ZnT8A\n5. Stimulated C-peptide of \u22650.2 pmol/mL measured during mixed-meal tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes\n6. HbA1c \u2264 10 %\n7. Body weight \u2265 35kg at screening\n8. Willing to comply with intensive diabetes management and wear a Continuous Glucose Monitoring Device (CGM)\n9. Participants who are Cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) seronegative at screening must be CMV and/or EBV Polymerase chain reaction (PCR) negative within 30 days of randomization and may not have had signs or symptoms of a CMV and/or EBV-compatible illness lasting longer than 7 days within 30 days of the baseline visit (V0).\n10. Participants who are CMV and/or EBV seropositive at screening must be CMV PCR negative and/or EBV PCR \\<2,000 IU/mL and must have no signs or symptoms of acute infection at the time of the baseline visit (V0).\n11. Be up to date on recommended vaccinations based on age of participants\\*\n12. Participants are required to receive killed influenza vaccination at least 2 weeks prior to the baseline visit (V0) when vaccine for the current or upcoming flu season is available.\n\n    Enrollment must be delayed at least 4 weeks from administration of a killed vaccine other than influenza and COVID-19 and 6 weeks from a live vaccination. Live vaccinations and non-live vaccinations (other than influzena and COVID-19) should not be given while on study drug and be postponed at least 3 months after the last dose of study drug.\n13. If participant is female with reproductive potential, she must have a negative pregnancy test at screening and be willing to avoid pregnancy using a highly-effective contraceptive method for the duration of the study\n14. Males of reproductive age must use a highly-effective contraceptive method during the treatment phase and for 3 months following last dose of study drug\n\n    * For COVID-19 vaccination, all participants will be strongly encouraged to be up-to-date with COVID-19 vaccine (s) as indicated by country-specific guidelines at least 2 weeks prior to the baseline visit (V0).",
        "ExclusionCriteria": "1. Current or ongoing use of non-insulin pharmaceuticals or medication that affect glycemic control or glucose homeostasis within 7 days prior to screening or any prohibited concomitant medication listed in section 4.8\n2. Untreated hypothyroidism or active Graves' disease\n3. Concurrent treatment with other immunosuppressive agents (including biologics or steroids), other than inhaled or topical glucocorticoids\n4. Active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 1 month prior to Day 0 or superficial skin infection within 1 week prior to Day 0\n5. Active acute or chronic infection requiring treatment with intravenous therapy (IV) within a minimum 1 month prior to Day 0\n\n   a. Specific cases should be reviewed by Infectious Disease Committee prior to enrollment\n6. Have active signs or symptoms of acute infection at the time of the baseline visit (V0).\n7. Significant trauma or major surgery within 1 month of signing informed consent.\n8. Considered in imminent need for surgery or with elective surgery scheduled to occur during the study\n9. History of disseminated herpes zoster or disseminated herpes simplex or a recurrent (more than one episode of) localized, dermatomal herpes zoster\n10. Have evidence of prior or current tuberculosis infection as assessed by Purified Protein Derivative (PPD), interferon gamma release assay (IGRA) or by history\n11. Have evidence of current or past HIV or Hepatitis B infection\n12. Have evidence of active Hepatitis C infection\n13. Have current, confirmed COVID-19 infection\n14. Current or history of Deep vein thrombosis (DVT), Pulmonary embolism (PE), or other thromboembolic events or history of inherited coagulopathies\n15. First degree relative with a history of unprovoked venous thromboembolism (i.e. without known underlying cause such as trauma, surgery, immobilization, prolonged travel, pregnancy, hormone use, or plaster cast), which suggests that a participant may be at increased risk of inherited coagulation disorder\n16. Any present malignancies or history of malignancy, other than a successfully treated nonmelanoma skin cancer\n17. History of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease\n18. Known or suspected polymorphism in the Cytochrome P450 2C19 (CYP2C19 gene, resulting in classification as a poor CYP2C19 metabolizer).\n19. Have renal impairment (eGFR\\< 60 mL/min)\n20. Currently on anti-platelet therapies, excluding low dose aspirin\n21. One or more screening laboratory values as stated\n\n    1. Neutrophils \\< 1,500 /\u03bcL\n    2. Lymphocytes \\< 800 /\u03bcL\n    3. Platelets \\< 150,000 / \u03bcL\n    4. Hemoglobin \\< 6.2 mmol/L (10.0 g/dL)\n    5. Potassium \\> 5.5 mmol/L or \\<3.0 mmol/L\n    6. Sodium \\> 150mmol/L or \\< 130mmol/L\n    7. AST or ALT \u2265 2.5 times the upper limit of normal\n    8. Bilirubin \u2265 1.5 times upper limit of normal unless diagnosed with Gilbert's syndrome\n    9. LDL \\>160 mg/dL\n22. Vaccination with a live virus within the last 6 weeks and killed vaccine within 4 weeks (except 2 weeks for flu vaccine and COVID vaccine)\n23. Be currently pregnant or lactating or anticipate becoming pregnant during the study\n24. Male participants able to father children and female participants of childbearing potential who are unwilling or unable to use 2 effective methods (at least 1 highly effective method) of contraception, including abstinence, as outlined in this protocol for the duration of the study and for at least 3 months after the last dose of investigational product\n25. Be currently participating in another T1D treatment study\n26. Have hearing loss with progression over the previous 5 years, or sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered acute, fluctuating, or progressive\n27. Acute coronary syndrome (e.g., myocardial infarction, unstable angina pectoris) and any history of cerebrovascular disease within 24 weeks before screening; Heart failure NYHA (New York Heart Association) III, NYHA IV\n28. ANY of the following conditions at screening:\n\n    a. Screening 12-lead electrocardiogram (ECG) that demonstrates: i. Clinically significant abnormalities requiring treatment (eg, acute myocardial infarction, serious tachy- or brady-arrhythmias) or indicating serious underlying heart disease (eg, cardiomyopathy, Wolff-Parkinson- White syndrome); ii. Confirmed QT corrected using Fridericia's correction factor (QTcF) prolongation (\\>450 milliseconds).\n\n    b. Long QT Syndrome, a family history of Long QT Syndrome, or a history of Torsades de Pointes (TdP).\n29. History of chronic alcohol abuse or intravenous drug abuse or other illicit drug abuse within 2 years prior to screening\n30. Current or past use of tobacco or nicotine containing products more than the equivalent of 5 cigarettes per day\n31. Participant is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the trial\n32. Have any complicating medical issues or abnormal clinical laboratory results that may interfere with study conduct, or cause increased risk\n33. Any condition that in the investigator's opinion may adversely affect study participation or may compromise the study results",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "12 Years",
        "NCTId": "NCT05743244",
        "startDate": "2023-10-19",
        "completionDate": "2027-06-30",
        "durationDays": 1350,
        "daysUntilEnd": 1055
    },
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n1. Age \u2265 8 and \u2264 45 years old at time of signing informed consent.\n2. Fulfill the ADA criteria for diagnosis of T1D within 100 days of randomization.\n3. Must be willing to provide informed consent or assent with a parent or legal guardian providing informed consent if \\< 18 years of age.\n4. Positive for at least one islet cell autoantibody; GAD65A, mIAA (if obtained within 10 days of the onset of insulin therapy), IA-2A, ICA, or ZnT8A\n5. Must have stimulated C-peptide of \u22650.2 pmol/mL measured during mixed-meal tolerance test (MMTT) conducted at least 21 days after the diagnosis of diabetes.\n6. Enrollees must be willing to comply with intensive diabetes management.\n7. Body weight must be \u2265 20.0 kg for study agent administration.\n8. Subjects who are CMV and/or EBV seronegative at screening must be CMV and/or EBV PCR negative and may not have had signs or symptoms of a CMV and/or EBV compatible illness prior to randomization.\n9. Female participants with reproductive potential must have a negative pregnancy test at screening and be willing to avoid pregnancy for the duration of treatment and until 3 months after the last dose of Abatacept. Female participants with reproductive potential who are sexually active will be instructed to use a highly effective contraceptive method until one year after the last dose of rituximab-pvvr.\n10. Male participants of reproductive age must use an adequate contraceptive method for the duration of rituximab-pvvr treatment and 12 months following the last dose of rituximab-pvvr.\n11. The following additional inclusion criteria regarding vaccines must be met:\n\n    1. More than 4 weeks from immunization with a live viral vaccine\n    2. Be up to date on all recommended vaccinations based on age of subject\\*\n    3. Receive non-live influenza vaccination at least 2 weeks prior to randomization when vaccine for the current or upcoming flu season is available\n    4. Willingness to forgo vaccines (other than killed influenza) during the 6 months after the rituximab-pvvr treatment period\n12. Participants must be willing to practice public health prevention measures such as social distancing, masking, and good hand hygiene, and/or receive therapeutics such as monoclonal antibodies and antivirals as directed by the study and recommended by local health authorities to prevent SARS-Cov-2 infection.\n13. Willing to wear a continuous glucose monitoring device for a minimum of 10 days every 6 months \\* Adult subjects must be fully immunized. Pediatric subjects who have not completed their primary vaccination schedule must receive all vaccinations allowable per local public health immunization guidelines for their current age prior to study drug delivery. Any remaining vaccinations should be given and continue per the schedule at least 6 months after rituximab-pvvr is administered. For COVID-19 vaccination, all participants will be strongly encouraged to be up-to-date with COVID-19 vaccine(s) as indicated by country-specific guidelines at least 2 weeks prior to randomization.\n\nExclusion Criteria:\n\n1. One or more screening laboratory values as stated:\n\n   1. Leukocytes \\<3,000/\u03bcL\n   2. Neutrophils \\<1,500/\u03bcL\n   3. Lymphocytes \\<800/\u03bcL\n   4. Platelets \\<100,000/\u03bcL\n   5. Hemoglobin \\<6.2 mmol/L (10.0 g/dL)\n   6. Potassium \\>5.5 mmol/L or \\<3.0 mmol/L\n   7. Sodium \\>150 mmol/L or \\<130 mmol/L\n   8. AST or ALT \u2265 2.5 times the upper limits of normal\n   9. Bilirubin \u2265 1.5 times upper limit of normal\n2. History of immune deficiency\n3. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within 7 days of screening visit.\n4. Chronic active infection other than localized skin infections.\n5. Have active signs or symptoms of acute infection at the time of randomization.\n6. Have IgG and/or IgM levels below the normal reference ranges.\n7. Positive PPD, interferon gamma release assay (IGRA) or history of previous treatment for TB.\n8. Vaccination with a live virus within 4 weeks prior to initiating study treatment.\n9. A history of confirmed infectious mononucleosis within the 3 months prior to initiating study treatment, as documented by EBV serology (EBV VCA-IgM and VCA-IgG; PCR would be confirmatory).\n10. Laboratory evidence of current or past HIV or Hepatitis B or active Hepatitis C infection.\n11. Be currently pregnant, lactating or anticipate pregnancy within 14 weeks of the last study drug administration (Visit 15).\n12. Chronic use of oral or inhaled steroids or other immunosuppressive agents.\n13. Known and untreated hypothyroidism or active Graves' disease at randomization.\n14. History of malignancy.\n15. Prior treatment with active study agent from a previous clinical trial.\n16. Any laboratory abnormality or condition that, in the opinion of the investigator, would interfere with the study conduct or the safety of the participant.",
        "InclusionCriteria": "1. Age \u2265 8 and \u2264 45 years old at time of signing informed consent.\n2. Fulfill the ADA criteria for diagnosis of T1D within 100 days of randomization.\n3. Must be willing to provide informed consent or assent with a parent or legal guardian providing informed consent if \\< 18 years of age.\n4. Positive for at least one islet cell autoantibody; GAD65A, mIAA (if obtained within 10 days of the onset of insulin therapy), IA-2A, ICA, or ZnT8A\n5. Must have stimulated C-peptide of \u22650.2 pmol/mL measured during mixed-meal tolerance test (MMTT) conducted at least 21 days after the diagnosis of diabetes.\n6. Enrollees must be willing to comply with intensive diabetes management.\n7. Body weight must be \u2265 20.0 kg for study agent administration.\n8. Subjects who are CMV and/or EBV seronegative at screening must be CMV and/or EBV PCR negative and may not have had signs or symptoms of a CMV and/or EBV compatible illness prior to randomization.\n9. Female participants with reproductive potential must have a negative pregnancy test at screening and be willing to avoid pregnancy for the duration of treatment and until 3 months after the last dose of Abatacept. Female participants with reproductive potential who are sexually active will be instructed to use a highly effective contraceptive method until one year after the last dose of rituximab-pvvr.\n10. Male participants of reproductive age must use an adequate contraceptive method for the duration of rituximab-pvvr treatment and 12 months following the last dose of rituximab-pvvr.\n11. The following additional inclusion criteria regarding vaccines must be met:\n\n    1. More than 4 weeks from immunization with a live viral vaccine\n    2. Be up to date on all recommended vaccinations based on age of subject\\*\n    3. Receive non-live influenza vaccination at least 2 weeks prior to randomization when vaccine for the current or upcoming flu season is available\n    4. Willingness to forgo vaccines (other than killed influenza) during the 6 months after the rituximab-pvvr treatment period\n12. Participants must be willing to practice public health prevention measures such as social distancing, masking, and good hand hygiene, and/or receive therapeutics such as monoclonal antibodies and antivirals as directed by the study and recommended by local health authorities to prevent SARS-Cov-2 infection.\n13. Willing to wear a continuous glucose monitoring device for a minimum of 10 days every 6 months \\* Adult subjects must be fully immunized. Pediatric subjects who have not completed their primary vaccination schedule must receive all vaccinations allowable per local public health immunization guidelines for their current age prior to study drug delivery. Any remaining vaccinations should be given and continue per the schedule at least 6 months after rituximab-pvvr is administered. For COVID-19 vaccination, all participants will be strongly encouraged to be up-to-date with COVID-19 vaccine(s) as indicated by country-specific guidelines at least 2 weeks prior to randomization.",
        "ExclusionCriteria": "1. One or more screening laboratory values as stated:\n\n   1. Leukocytes \\<3,000/\u03bcL\n   2. Neutrophils \\<1,500/\u03bcL\n   3. Lymphocytes \\<800/\u03bcL\n   4. Platelets \\<100,000/\u03bcL\n   5. Hemoglobin \\<6.2 mmol/L (10.0 g/dL)\n   6. Potassium \\>5.5 mmol/L or \\<3.0 mmol/L\n   7. Sodium \\>150 mmol/L or \\<130 mmol/L\n   8. AST or ALT \u2265 2.5 times the upper limits of normal\n   9. Bilirubin \u2265 1.5 times upper limit of normal\n2. History of immune deficiency\n3. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within 7 days of screening visit.\n4. Chronic active infection other than localized skin infections.\n5. Have active signs or symptoms of acute infection at the time of randomization.\n6. Have IgG and/or IgM levels below the normal reference ranges.\n7. Positive PPD, interferon gamma release assay (IGRA) or history of previous treatment for TB.\n8. Vaccination with a live virus within 4 weeks prior to initiating study treatment.\n9. A history of confirmed infectious mononucleosis within the 3 months prior to initiating study treatment, as documented by EBV serology (EBV VCA-IgM and VCA-IgG; PCR would be confirmatory).\n10. Laboratory evidence of current or past HIV or Hepatitis B or active Hepatitis C infection.\n11. Be currently pregnant, lactating or anticipate pregnancy within 14 weeks of the last study drug administration (Visit 15).\n12. Chronic use of oral or inhaled steroids or other immunosuppressive agents.\n13. Known and untreated hypothyroidism or active Graves' disease at randomization.\n14. History of malignancy.\n15. Prior treatment with active study agent from a previous clinical trial.\n16. Any laboratory abnormality or condition that, in the opinion of the investigator, would interfere with the study conduct or the safety of the participant.",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "8 Years",
        "NCTId": "NCT03929601",
        "startDate": "2023-10-30",
        "completionDate": "2029-10",
        "durationDays": 2163,
        "daysUntilEnd": 1879
    },
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n1. Participant is a male or female 0 to \\< 8 years of age, inclusive, at Day 1\n2. Participant has Stage 2 T1D (two T1D-related autoantibodies and dysglycemia)\n\nExclusion Criteria:\n\n1. Participant has any autoimmune disease other than T1D with the exception of stable thyroid or celiac disease\n2. Has an active infection and/or fever\n3. Has a history of or serologic evidence at screening of current or past infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).\n4. Has any condition that, in the opinion of the Investigator, would interfere with the study conduct or the safety of the participant.",
        "InclusionCriteria": "1. Participant is a male or female 0 to \\< 8 years of age, inclusive, at Day 1\n2. Participant has Stage 2 T1D (two T1D-related autoantibodies and dysglycemia)",
        "ExclusionCriteria": "1. Participant has any autoimmune disease other than T1D with the exception of stable thyroid or celiac disease\n2. Has an active infection and/or fever\n3. Has a history of or serologic evidence at screening of current or past infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).\n4. Has any condition that, in the opinion of the Investigator, would interfere with the study conduct or the safety of the participant.",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "0 Years",
        "NCTId": "NCT05757713",
        "startDate": "2023-07-25",
        "completionDate": "2026-10",
        "durationDays": 1164,
        "daysUntilEnd": 783
    },
    {
        "EligibilityCriteria": "Inclusion Criteria\n\n1. Subject is age 2-80 years at time of screening\n\n   1. US, Canada, Australia and New Zealand: Subjects 2-80 years of age will be allowed to enroll in the post approval study.\n   2. Europe: Only subjects \u22657 years of age are allowed to enroll in the post-market study.\n2. Subjects who are 2-21 years are determined by the investigator to have the appropriate, requisite support (family, caregiver or social network) to successfully participate in this study\n3. Subject must have a minimum daily insulin requirement (Total Daily Dose) of equal to or greater than 8 units/day\n4. Subjects who are determined by the investigator to be psychologically sound in order to successfully participate in this study\n5. Subject has been diagnosed with type 1 diabetes for at least three months Note: Determination of classification for diabetes will be based on American Diabetes Association Clinical Practice Guidelines accounting for several patient characteristics such as: age of onset, patient's weight or BMI, history of diabetic ketoacidosis, history of therapy management, if available in the medical records.\n6. Subject must be on one of the following management therapies:\n\n   1. Multiple daily injections defined by use of rapid analogue with meals and approved long acting analogue (e.g. detemir or glargine) with or without CGM\n   2. Insulin pump therapy with or without CGM\n7. Subject is willing to perform \u2265 4 finger stick blood glucose measurements daily\n8. Subject is willing to perform required study procedures\n9. Subject is willing to wear the system continuously throughout the study for at least 80% of the time.\n10. Subject is willing to upload data at least weekly from the study pump/meter, must have Internet access and a computer system that meets the requirements for uploading the study pump/meter for data collection\n11. Subject must be willing to use the study glucose meter system (i.e. along with study meter strips).\n12. If subject has celiac disease, it has been adequately treated as determined by the investigator\n13. Subject with the diagnosis of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease, within 1 year of screening, will be included in the study with the consent of the Investigator\n14. Subject is willing to take one of the following insulins and can financially afford to use either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount)\n\n    1. Humalog\u00ae (insulin lispro injection)\n    2. NovoLog\u00ae (insulin aspart)\n\nExclusion Criteria:\n\n1. Subject participated in any Closed Loop study in the past.\n2. Subject is unable to tolerate tape adhesive in the area of sensor placement\n3. Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, rash, Staphylococcus infection) or area of infusion set placement\n4. Women of child-bearing potential who have a positive pregnancy test at screening or plan to become pregnant during the course of the study\n5. Subject is being treated for hyperthyroidism at time of screening\n6. Subject has an abnormality (out of reference range) in thyroid-stimulating hormone (TSH) at time of screening visit. TSH is not required for subjects 2-13 years of age.\n7. Subject has taken any oral, injectable, or IV glucocorticoids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study.\n8. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks\n9. Subject is currently abusing illicit drugs or marijuana\n10. Subject is currently abusing prescription drugs\n11. Subject is currently abusing alcohol\n12. Subject is using pramlintide (Symlin), SGLT2 inhibitors, GLP agonists, biguanides, DPP-4 inhibitors or sulfonylureas at time of screening\n13. Subject is using hydroxyurea at the time of screening or plans to use it during the study\n14. Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator\n15. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening\n16. Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation\n17. Subject diagnosed with current moderate to severe eating disorder such as anorexia or bulimia\n18. Subject has been diagnosed with chronic kidney disease requiring dialysis or resulting in chronic anemia\n19. Subjects who are currently being actively treated for cancer.\n20. Subject who is designated as a research staff member for this study",
        "InclusionCriteria": "1. Subject is age 2-80 years at time of screening\n\n   1. US, Canada, Australia and New Zealand: Subjects 2-80 years of age will be allowed to enroll in the post approval study.\n   2. Europe: Only subjects \u22657 years of age are allowed to enroll in the post-market study.\n2. Subjects who are 2-21 years are determined by the investigator to have the appropriate, requisite support (family, caregiver or social network) to successfully participate in this study\n3. Subject must have a minimum daily insulin requirement (Total Daily Dose) of equal to or greater than 8 units/day\n4. Subjects who are determined by the investigator to be psychologically sound in order to successfully participate in this study\n5. Subject has been diagnosed with type 1 diabetes for at least three months Note: Determination of classification for diabetes will be based on American Diabetes Association Clinical Practice Guidelines accounting for several patient characteristics such as: age of onset, patient's weight or BMI, history of diabetic ketoacidosis, history of therapy management, if available in the medical records.\n6. Subject must be on one of the following management therapies:\n\n   1. Multiple daily injections defined by use of rapid analogue with meals and approved long acting analogue (e.g. detemir or glargine) with or without CGM\n   2. Insulin pump therapy with or without CGM\n7. Subject is willing to perform \u2265 4 finger stick blood glucose measurements daily\n8. Subject is willing to perform required study procedures\n9. Subject is willing to wear the system continuously throughout the study for at least 80% of the time.\n10. Subject is willing to upload data at least weekly from the study pump/meter, must have Internet access and a computer system that meets the requirements for uploading the study pump/meter for data collection\n11. Subject must be willing to use the study glucose meter system (i.e. along with study meter strips).\n12. If subject has celiac disease, it has been adequately treated as determined by the investigator\n13. Subject with the diagnosis of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease, within 1 year of screening, will be included in the study with the consent of the Investigator\n14. Subject is willing to take one of the following insulins and can financially afford to use either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount)\n\n    1. Humalog\u00ae (insulin lispro injection)\n    2. NovoLog\u00ae (insulin aspart)",
        "ExclusionCriteria": "1. Subject participated in any Closed Loop study in the past.\n2. Subject is unable to tolerate tape adhesive in the area of sensor placement\n3. Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, rash, Staphylococcus infection) or area of infusion set placement\n4. Women of child-bearing potential who have a positive pregnancy test at screening or plan to become pregnant during the course of the study\n5. Subject is being treated for hyperthyroidism at time of screening\n6. Subject has an abnormality (out of reference range) in thyroid-stimulating hormone (TSH) at time of screening visit. TSH is not required for subjects 2-13 years of age.\n7. Subject has taken any oral, injectable, or IV glucocorticoids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study.\n8. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks\n9. Subject is currently abusing illicit drugs or marijuana\n10. Subject is currently abusing prescription drugs\n11. Subject is currently abusing alcohol\n12. Subject is using pramlintide (Symlin), SGLT2 inhibitors, GLP agonists, biguanides, DPP-4 inhibitors or sulfonylureas at time of screening\n13. Subject is using hydroxyurea at the time of screening or plans to use it during the study\n14. Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator\n15. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening\n16. Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation\n17. Subject diagnosed with current moderate to severe eating disorder such as anorexia or bulimia\n18. Subject has been diagnosed with chronic kidney disease requiring dialysis or resulting in chronic anemia\n19. Subjects who are currently being actively treated for cancer.\n20. Subject who is designated as a research staff member for this study",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "2 Years",
        "NCTId": "NCT02748018",
        "startDate": "2017-05-25",
        "completionDate": "2024-09",
        "durationDays": 2656,
        "daysUntilEnd": 23
    },
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n1. Males and females 6- \u226540 years of age with a clinical diagnosis of T1D\n2. T1D clinical diagnosis with insulin start date no more than 100 days prior to the time of randomization\n3. Random non-fasting C-peptide level of \\>0.2 pmol/mL (equivalent to \\>0.6ng/ml) at screening.\n4. Positive for any one of the following diabetes-related autoantibodies (IAA, GAA, IA-2, or ZnT8)\n5. Treatment na\u00efve of any immunomodulatory agent\n6. Normal hearing at screening, defined as acceptable results of pure-tone audiometry (\\<20 decibel \\[dB\\] baseline thresholds for frequencies 250, 500, 1000, and 2000 Hz\n\nExclusion Criteria:\n\n1. Presence of severe, active disease that interferes with dietary intake or requires the use of chronic medication, with the exception of well-controlled hypothyroidism and mild asthma not requiring oral steroids. Presence of any psychiatric disorder that will affect ability to participate in study.\n2. Diabetes other than T1D\n3. Chronic illness known to affect glucose metabolism (e.g. Cushing syndrome, polycystic ovarian disorder, cystic fibrosis) or taking medications that affect glucose metabolism (e.g. steroids, metformin)\n4. Inability to swallow pills\n5. Psychiatric impairment or current use of anti-psychotic medication\n6. Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results.\n7. Neutropenia (\\< 1,500 neutrophils/\u03bcL)\n8. Leukopenia (\\< 3,000 leukocytes /\u03bcL)\n9. Lymphopenia ( \\< 800 lymphocytes/\u03bcL)\n10. Thrombocytopenia (\\<100,000 platelets/\u03bcL)\n11. Clinically significant anemia or Hemoglobin as defined below:\n\n    In Adults: Hgb \\<12.0g/dL in females and \\<13.0g/dL in males In Children: 12- \\<18: \\<11.4 g/dL in females and \\<12.4 g/dL in males In Children: 6- \\<12: Hgb \\<11.2 g/dL\n12. Impaired renal function (assessed by history and BUN/Creatinine, DFMO is renally excreted)\n13. Allergy to milk or soy (components of Boost\u00ae drink used for mixed meal tolerance testing)\n14. Female participants of child-bearing age with reproductive potential, must not be pregnant and agree to use 2 effective forms of birth control or be abstinent during the study period (see below). Male participants (including men who have had vasectomies) whose partners are pregnant or may be pregnant should use condoms while on study drug, until 2 weeks after discontinuation of drug, while the partner is pregnant.\n15. Active seizure disorder, defined as requiring chronic medication at the time of study or having had a seizure within the past 12 months at the time of screening\n16. Enrollment into another intervention trial.",
        "InclusionCriteria": "1. Males and females 6- \u226540 years of age with a clinical diagnosis of T1D\n2. T1D clinical diagnosis with insulin start date no more than 100 days prior to the time of randomization\n3. Random non-fasting C-peptide level of \\>0.2 pmol/mL (equivalent to \\>0.6ng/ml) at screening.\n4. Positive for any one of the following diabetes-related autoantibodies (IAA, GAA, IA-2, or ZnT8)\n5. Treatment na\u00efve of any immunomodulatory agent\n6. Normal hearing at screening, defined as acceptable results of pure-tone audiometry (\\<20 decibel \\[dB\\] baseline thresholds for frequencies 250, 500, 1000, and 2000 Hz",
        "ExclusionCriteria": "1. Presence of severe, active disease that interferes with dietary intake or requires the use of chronic medication, with the exception of well-controlled hypothyroidism and mild asthma not requiring oral steroids. Presence of any psychiatric disorder that will affect ability to participate in study.\n2. Diabetes other than T1D\n3. Chronic illness known to affect glucose metabolism (e.g. Cushing syndrome, polycystic ovarian disorder, cystic fibrosis) or taking medications that affect glucose metabolism (e.g. steroids, metformin)\n4. Inability to swallow pills\n5. Psychiatric impairment or current use of anti-psychotic medication\n6. Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results.\n7. Neutropenia (\\< 1,500 neutrophils/\u03bcL)\n8. Leukopenia (\\< 3,000 leukocytes /\u03bcL)\n9. Lymphopenia ( \\< 800 lymphocytes/\u03bcL)\n10. Thrombocytopenia (\\<100,000 platelets/\u03bcL)\n11. Clinically significant anemia or Hemoglobin as defined below:\n\n    In Adults: Hgb \\<12.0g/dL in females and \\<13.0g/dL in males In Children: 12- \\<18: \\<11.4 g/dL in females and \\<12.4 g/dL in males In Children: 6- \\<12: Hgb \\<11.2 g/dL\n12. Impaired renal function (assessed by history and BUN/Creatinine, DFMO is renally excreted)\n13. Allergy to milk or soy (components of Boost\u00ae drink used for mixed meal tolerance testing)\n14. Female participants of child-bearing age with reproductive potential, must not be pregnant and agree to use 2 effective forms of birth control or be abstinent during the study period (see below). Male participants (including men who have had vasectomies) whose partners are pregnant or may be pregnant should use condoms while on study drug, until 2 weeks after discontinuation of drug, while the partner is pregnant.\n15. Active seizure disorder, defined as requiring chronic medication at the time of study or having had a seizure within the past 12 months at the time of screening\n16. Enrollment into another intervention trial.",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "4 Years",
        "NCTId": "NCT05594563",
        "startDate": "2023-03-14",
        "completionDate": "2027-12",
        "durationDays": 1723,
        "daysUntilEnd": 1209
    },
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n1. Willing to provide informed consent or have a parent or legal guardian provide informed consent when the subject is \\<18 years of age.\n2. Age greater than or equal to 6 and \\< 35 years\n3. At least two or more diabetes-related biochemical autoantibodies (mIAA, GADA, ICA, IA-2A, ZnT8A) present on the same sample. In the absence of other antibodies, ICA and GADA positivity alone will not suffice for eligibility in this trial.\n4. Weight greater than the 5th percentile for age and sex.\n5. BMI \\< 95th and \\> 5th percentile for age for those under age 18 years and \\< 30 and \\> 15 for adults (\u2265 18)\n6. ADA Stage 2 criteria\\* AND at least one of the following high-risk markers (occurring at the same visit) within 7 weeks (52 days) of randomization, defined below (for defining a 2-year 50% risk for progression to Stage 3 T1D):\n\n   a. HbA1c \u2265 5.7 and \\<6.5% b. Index60 \u2265 1.4 i. Index60 = 0.3695 \u00d7 (log fasting C-peptide \\[ng/mL\\]) + 0.0165 \u00d7 60-min glucose (mg/dL) - 0.3644 \u00d7 60-min C-peptide (ng/mL) c. DPTRS \u2265 7.4 DPTRS = (1.57 x log BMI) - (0.06 x age) + (0.81 x glucose sum from 30 to 120 min/100) - (0.85 x C-peptide sum from 30 to 120 min/10) + (0.48 x log fasting C-peptide)\n\n   \\*Dysglycemia is defined as 2-hr glucose \u2265 140 and \\<200 mg/dL or fasting glucose \u2265 110 and \\<126 or 30, 60, or 90 minute glucose \u2265 200 mg/dL from OGTT\n7. All subjects must be CMV and EBV PCR negative within 30 days of randomization and may not have had signs or symptoms of a CMV or EBV-compatible illness lasting longer than 7 days within 30 days of randomization\n8. Seated blood pressure less than 130/80 mmHg for participants \u2265 18 years. For participants \\< 18 years seated blood pressure less than 95th percentile for age, sex and height.\n9. Be at least 4 weeks from last live immunization\n10. Participants are required to receive non-live influenza vaccination at least 2 weeks prior to randomization when vaccine for the current or upcoming flu season is available.\n11. Participants must also have a negative COVID-19 test within 7 days of the first day of treatment if otherwise eligible\n12. Willingness to comply with study directed social distancing and protection from SARS-Cov-2 infection.\n13. Be willing to forgo vaccines (other than killed influenza) during the 3 months after study drug treatment period (Days 0 and 1)\n14. Be up to date on all recommended vaccinations based on age of subject\\*\n15. With the exception of stage 2 T1D, subjects must be healthy, as defined by absence of any other untreated diagnoses that the protocol committee deems to be a potential confounder.\n16. If a female participant with reproductive potential, willing to avoid pregnancy (abstinence or adequate contraceptive method) through the completion of the study infusions and up to 3 months after study drug administration and undergo pregnancy testing prior to each study visit.\n17. Must be residing or have accommodations within 1 hour of the infusion site during the two days of study drug infusions and must be within 1 hour of a medical care facility for 1 day after completion of infusion 2.\n18. Participants must live in a location with rapid access to emergency medical services.\n\n    * Adult participants must be fully immunized. Pediatric participants who have not completed their primary vaccination schedule must receive all vaccinations allowable per the national/country-specific immunization guidelines for their current age prior to study drug delivery. Any remaining vaccinations should be given and continue per the schedule at least 3 months after study drug is administered. For COVID-19 vaccination, all participants will be strongly encouraged to be up-to-date with COVID-19 vaccine(s) as indicated by country-specific guidelines at least 2 weeks prior to randomization.\n\nExclusion Criteria:\n\n1. Immunodeficiency or clinically significant chronic lymphopenia: (Leukopenia (\\< 3,000 leukocytes /\u03bcL), neutropenia (\\<1,500 neutrophils/\u03bcL), lymphopenia (\\<800 lymphocytes/\u03bcL), thrombocytopenia (\\<100,000 platelets/\u03bcL).\n2. Hemoglobin less than 13.5 g/dL for adult men and less than 12 g/dL for adult females and less than 11 g/dL for participants under age 18\n3. Active signs or symptoms of acute infection at the time of randomization including SARS-Cov-2.\n4. Uncontrolled autoimmune thyroid disease and/or celiac disease (participants must be well controlled for the previous 6 months).\n5. Evidence of prior or current tuberculosis infection as assessed interferon gamma release assay (QuantiFERON).\n6. Currently pregnant or lactating or anticipate getting pregnant within the study period.\n7. Require use of other immunosuppressive agents including chronic use of systemic steroids.\n8. Evidence of current or past HIV or Hepatitis B or current Hepatitis C infection.\n9. Any complicating medical issues or abnormal clinical laboratory results that may interfere with study conduct, or cause increased risk to include pre-existing cardiac disease, COPD, sickle cell disease, neurological disease, or blood count abnormalities.\n10. A history of malignancies other than of skin.\n11. Evidence of liver dysfunction with AST or ALT outside of the reference range.\n12. Evidence of renal dysfunction with creatinine outside of the reference range.\n13. Increased bilirubin (total and direct) outside of the normal limit (Participants with documentation of Gilbert's Disease permitted).\n14. Vaccination with a live virus within the last 4 weeks.\n15. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within 7 days of screening\n16. Prior treatment with Teplizumab (either in a previous clinical trial or clinically).\n17. Has participated in a clinical trial for diabetes prevention previously and received active study agent within 3 months of randomization.\n18. Known allergy to ATG or any product excipient\n19. Prior treatment with ATG or known allergy to rabbit-derived products or to any product excipient\n20. Prior adverse reactions to heparin.\n21. Any condition that in the investigator's opinion may adversely affect study participation will be reviewed by the Study Chair to ensure consistency and adjudicate whether or not the subject may compromise the study results\n22. Any screening/baseline laboratory result not otherwise stated out of normal reference range and/or medical history that may increase the risk of the subject's participation in this trial.\n23. Previously diagnosed with Stage 3 TID according to ADA criteria (see Appendix 3 for Criteria for diagnosis of diabetes)",
        "InclusionCriteria": "1. Willing to provide informed consent or have a parent or legal guardian provide informed consent when the subject is \\<18 years of age.\n2. Age greater than or equal to 6 and \\< 35 years\n3. At least two or more diabetes-related biochemical autoantibodies (mIAA, GADA, ICA, IA-2A, ZnT8A) present on the same sample. In the absence of other antibodies, ICA and GADA positivity alone will not suffice for eligibility in this trial.\n4. Weight greater than the 5th percentile for age and sex.\n5. BMI \\< 95th and \\> 5th percentile for age for those under age 18 years and \\< 30 and \\> 15 for adults (\u2265 18)\n6. ADA Stage 2 criteria\\* AND at least one of the following high-risk markers (occurring at the same visit) within 7 weeks (52 days) of randomization, defined below (for defining a 2-year 50% risk for progression to Stage 3 T1D):\n\n   a. HbA1c \u2265 5.7 and \\<6.5% b. Index60 \u2265 1.4 i. Index60 = 0.3695 \u00d7 (log fasting C-peptide \\[ng/mL\\]) + 0.0165 \u00d7 60-min glucose (mg/dL) - 0.3644 \u00d7 60-min C-peptide (ng/mL) c. DPTRS \u2265 7.4 DPTRS = (1.57 x log BMI) - (0.06 x age) + (0.81 x glucose sum from 30 to 120 min/100) - (0.85 x C-peptide sum from 30 to 120 min/10) + (0.48 x log fasting C-peptide)\n\n   \\*Dysglycemia is defined as 2-hr glucose \u2265 140 and \\<200 mg/dL or fasting glucose \u2265 110 and \\<126 or 30, 60, or 90 minute glucose \u2265 200 mg/dL from OGTT\n7. All subjects must be CMV and EBV PCR negative within 30 days of randomization and may not have had signs or symptoms of a CMV or EBV-compatible illness lasting longer than 7 days within 30 days of randomization\n8. Seated blood pressure less than 130/80 mmHg for participants \u2265 18 years. For participants \\< 18 years seated blood pressure less than 95th percentile for age, sex and height.\n9. Be at least 4 weeks from last live immunization\n10. Participants are required to receive non-live influenza vaccination at least 2 weeks prior to randomization when vaccine for the current or upcoming flu season is available.\n11. Participants must also have a negative COVID-19 test within 7 days of the first day of treatment if otherwise eligible\n12. Willingness to comply with study directed social distancing and protection from SARS-Cov-2 infection.\n13. Be willing to forgo vaccines (other than killed influenza) during the 3 months after study drug treatment period (Days 0 and 1)\n14. Be up to date on all recommended vaccinations based on age of subject\\*\n15. With the exception of stage 2 T1D, subjects must be healthy, as defined by absence of any other untreated diagnoses that the protocol committee deems to be a potential confounder.\n16. If a female participant with reproductive potential, willing to avoid pregnancy (abstinence or adequate contraceptive method) through the completion of the study infusions and up to 3 months after study drug administration and undergo pregnancy testing prior to each study visit.\n17. Must be residing or have accommodations within 1 hour of the infusion site during the two days of study drug infusions and must be within 1 hour of a medical care facility for 1 day after completion of infusion 2.\n18. Participants must live in a location with rapid access to emergency medical services.\n\n    * Adult participants must be fully immunized. Pediatric participants who have not completed their primary vaccination schedule must receive all vaccinations allowable per the national/country-specific immunization guidelines for their current age prior to study drug delivery. Any remaining vaccinations should be given and continue per the schedule at least 3 months after study drug is administered. For COVID-19 vaccination, all participants will be strongly encouraged to be up-to-date with COVID-19 vaccine(s) as indicated by country-specific guidelines at least 2 weeks prior to randomization.",
        "ExclusionCriteria": "1. Immunodeficiency or clinically significant chronic lymphopenia: (Leukopenia (\\< 3,000 leukocytes /\u03bcL), neutropenia (\\<1,500 neutrophils/\u03bcL), lymphopenia (\\<800 lymphocytes/\u03bcL), thrombocytopenia (\\<100,000 platelets/\u03bcL).\n2. Hemoglobin less than 13.5 g/dL for adult men and less than 12 g/dL for adult females and less than 11 g/dL for participants under age 18\n3. Active signs or symptoms of acute infection at the time of randomization including SARS-Cov-2.\n4. Uncontrolled autoimmune thyroid disease and/or celiac disease (participants must be well controlled for the previous 6 months).\n5. Evidence of prior or current tuberculosis infection as assessed interferon gamma release assay (QuantiFERON).\n6. Currently pregnant or lactating or anticipate getting pregnant within the study period.\n7. Require use of other immunosuppressive agents including chronic use of systemic steroids.\n8. Evidence of current or past HIV or Hepatitis B or current Hepatitis C infection.\n9. Any complicating medical issues or abnormal clinical laboratory results that may interfere with study conduct, or cause increased risk to include pre-existing cardiac disease, COPD, sickle cell disease, neurological disease, or blood count abnormalities.\n10. A history of malignancies other than of skin.\n11. Evidence of liver dysfunction with AST or ALT outside of the reference range.\n12. Evidence of renal dysfunction with creatinine outside of the reference range.\n13. Increased bilirubin (total and direct) outside of the normal limit (Participants with documentation of Gilbert's Disease permitted).\n14. Vaccination with a live virus within the last 4 weeks.\n15. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within 7 days of screening\n16. Prior treatment with Teplizumab (either in a previous clinical trial or clinically).\n17. Has participated in a clinical trial for diabetes prevention previously and received active study agent within 3 months of randomization.\n18. Known allergy to ATG or any product excipient\n19. Prior treatment with ATG or known allergy to rabbit-derived products or to any product excipient\n20. Prior adverse reactions to heparin.\n21. Any condition that in the investigator's opinion may adversely affect study participation will be reviewed by the Study Chair to ensure consistency and adjudicate whether or not the subject may compromise the study results\n22. Any screening/baseline laboratory result not otherwise stated out of normal reference range and/or medical history that may increase the risk of the subject's participation in this trial.\n23. Previously diagnosed with Stage 3 TID according to ADA criteria (see Appendix 3 for Criteria for diagnosis of diabetes)",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "6 Years",
        "NCTId": "NCT04291703",
        "startDate": "2023-11-01",
        "completionDate": "2029-12-31",
        "durationDays": 2252,
        "daysUntilEnd": 1970
    },
    {
        "EligibilityCriteria": "Inclusion Criteria\n\nSubjects must meet all of the following criteria for inclusion in the study:\n\n1. Males and non-pregnant non-lactating females\n2. Age between 21 and 70 years (both inclusive)\n3. Subjects on at least one glucose lowering agent (GLA) with no changes in GLA medications or dosing for at least 12 weeks prior to the screening visit\n\n   Permitted GLAs include:\n   * Metformin,\n   * GLP-1 RA including dual peptide agonists and related molecules (e.g., GLP-1/GIP RA),\n   * DPP-4i,\n   * TZDs,\n   * SGLT2is,\n   * SUs,\n   * Meglitinides,\n   * Insulin (basal or basal combined with short-acting), up to a total of 100 units daily\n4. HbA1c of 7.5%-10% (both inclusive)\n5. BMI \\>24 to \u226440 kg/m2\n6. WOCBP should have a negative urine beta hCG pregnancy test and must agree to use two of the established contraceptive methods throughout the study duration\n7. Able to sign an ICF and comply with study requirements\n\nExclusion Criteria\n\nSubjects who meet any of the following exclusion criteria are not allowed to be included in the study:\n\n1. FPG \u2265270 mg/dL\n2. Known case of absolute insulin deficiency as indicated by clinical assessment or a fasting plasma C-peptide of \\<0.6 ng/mL\n3. Subjects on any other class of glucose-lowering agents other than GLAs listed in inclusion criteria Any drugs or concomitant medications (e.g., psychoactive drugs such as carbamazepine phenobarbital; sympathomimetics such as ephedrine corticosteroids; anabolic steroids and male sex hormones such as testosterone) that can interfere with glucose metabolism (refer to prohibited medication on Appendix D: Eligibility Criteria Checklist)\n4. Recurrent or severe urinary tract or genital mycotic infections or history of GU infection within 4 weeks prior to informed consent, for those subjects on SGLT-2\n5. ALT or AST \\>3 times upper limit of normal (ULN) for the reference range, as determined by the central laboratory at screening visit. Patients with NAFLD are eligible if their ALT level is \u22643.0 times the ULN.\n6. Use of an investigational drug within 1 month or 5 half-lives (whichever is longer) before screening\n7. Diagnosed with type 1 diabetes or with a recent history of DKA within one year prior to screening\n8. Ketosis-prone T2D\n9. Known diabetes related non-healing ulcers or amputations (with the exception of a finger or toe amputation occurring \\> 1 year prior to screening.\n10. History of more than 1 severe hypoglycemia episode or hypoglycemia unawareness within the last 6 months\n11. Clinically significant hypoglycemia occurring during the run-in period, defined as a) 2 or more glucose alert values of \u226470 mg/dL (3.9 mmol/L) unless a clear, correctable, precipitating factor can be identified; b) clinically significant hypoglycemia with self-monitored or laboratory plasma glucose level \\<54 mg/dL (3.0 mmol/L); or c) severe hypoglycemic episode requiring third party assistance\n12. Known intestinal autoimmune disease including celiac disease, ulcerative colitis, Crohn's disease, lupus erythematosus, scleroderma, or other autoimmune connective tissue disorder that affects the small intestine\n13. Secondary hypothyroidism or inadequately controlled primary hypothyroidism (thyroid stimulating hormone \\[TSH\\] value outside the normal range at screening as determined by the central laboratory).\n14. Known thyroid cancer or hyperthyroidism with treatment within the past 12 months or inadequately controlled hyperthyroidism (TSH value outside the normal range at screening as determined by the central laboratory).\n15. An uncontrolled endocrine condition such as multiple endocrine neoplasia (except T2D)\n16. Known structural or functional disorder of the esophagus including any swallowing disorder, esophageal chest pain disorders, drug-refractory esophageal reflux symptoms, or active and uncontrolled gastroesophageal reflux disease (GERD) (defined as Los Angeles Grade C or D esophagitis)\n17. Known structural or functional disorder of the stomach including active gastric ulcer, chronic gastritis, gastric varices, hiatal hernia (a large hiatal hernia or type II and higher paraoesophageal hernia), cancer, or any other disorder of the stomach\n18. Previous GI surgery that could affect the ability to treat the duodenum such as subjects who have had a Billroth 2, Roux-en-Y gastric bypass, gastric sleeve, or other similar procedures or conditions\n19. Known history of chronic pancreatitis or a recent history of acute pancreatitis within the past year\n20. Presence of acute or chronic active hepatitis B or C (except if hepatitis C is cured) or cirrhosis, hepatic decompensation/acute liver disease during the last 6 months, or alcoholic or autoimmune chronic hepatitis\n21. Symptomatic gallstones, symptomatic kidney stones, or acute cholecystitis\n22. Clinically active systemic infection\n23. Known immunocompromised status including but not limited to individuals who have undergone organ transplantation, chemotherapy, or radiotherapy within the past 12 months; have clinically significant leukopenia; are positive for the human immunodeficiency virus (HIV); are on potential immunosuppressants; or individuals whose immune status makes the subject a poor candidate for clinical trial participation in the opinion of the investigator\n24. Known active malignancy or partial remission from clinically significant malignancy within the past 5 years (except basal or squamous cell skin cancer, carcinoma in situ, those who received curative treatment and are in complete remission for 5 years, or if the subject is confirmed as cancer free)\n25. Known active coagulopathy or current upper gastro-intestinal bleeding conditions such as ulcers, gastric varices, strictures, or congenital or acquired intestinal telangiectasia\n26. Known cases of sickle cell anemia, thalassemia, or conditions that affect red blood cell (RBC) turnover such as a recent blood transfusion within 90 days. Current persistent anemia, defined as hemoglobin \\<10g/dL\n27. Use of anticoagulation therapy (e.g., warfarin, coumadin, or novel oral anticoagulants \\[NOACs\\]) or anti-platelet agents (e.g., thienopyridine) which cannot be discontinued for 5-7 days or 2 drug half-lives before the procedure\n28. Use of systemic glucocorticoids (excluding topical or ophthalmic applications or inhaled forms) for more than 10 consecutive days within 90 days prior to screening\n29. Use of non-GLA drugs known to affect GI motility (e.g., metoclopramide)\n30. Known moderate to severe chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) of \\<45 mL/min/1.73m2 (estimated by Modification of Diet in Renal Disease \\[MDRD\\]), end-stage renal failure, or on dialysis\n31. History of myocardial infarction, stroke, transient ischemic attack, coronary artery intervention, CHF exacerbation, or any other major cardiac event requiring hospitalization within the last 6 months prior to screening or any cardiac history that would deem subject not eligible for anesthesia (unless documented clearance by cardiologist and/or treating endoscopy team)\n32. History of new or worsening signs or symptoms of coronary heart disease (CHD) within the last 3 months\n33. Known case of severe peripheral vascular disease, defined as AMA Criteria Class 1 or greater75 (Appendix 19.8)\n34. Known case of symptomatic heart failure with reduced ejection fraction (NYHA Class II-IV) requiring pharmacologic therapy to control symptoms\n35. Clinically significant electrocardiogram (ECG) findings such as new clinically significant arrhythmia, ST segment changes, or other conduction disturbances that increase risk of heart disease and require intervention as determined by the investigator\n36. Subjects who are at risk of pancreatitis, particularly those with a recent fasting triglyceride value of \\>600 mg/dL within the past 3 months\n37. Actively participating in a weight-loss program and currently not in the maintenance phase\n38. General contraindications to deep or conscious sedation, general anesthesia, high risk as determined by anesthesiologist (e.g., ASA score 4 or higher), or contraindications to upper GI endoscopy\n39. History of substance use disorder based on the DSM-5 criteria76 within the last 12 months (American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition).\n40. Use of weight loss medication such as Meridia, Xenical, over-the-counter weight-loss medications, or other prescribed medications used specifically for the purpose of weight loss\n41. Use of dietary supplements or herbal preparations that may have unknown effects on glycemic control or risk of bleeding\n42. Participating in another ongoing clinical trial of an investigational drug or device\n43. History of non-adherence to treatment in the previous 6 months, as determined by the investigator based on patient history, HbA1c value, or drug accountability\n44. Any other mental or physical condition which, in the opinion of the investigator, makes the subject a poor candidate for clinical-trial participation. Physical conditions assessed via endoscopy prior to participant study enrollment at visit 4 include, but not limited to:\n\n    1. Active and uncontrolled gastroesophageal reflux disease (GERD) defined as Los Angeles Grade C or D esophagitis\n    2. Abnormalities of the GI tract preventing endoscopic access to the duodenum\n    3. Anatomic abnormalities in the duodenum that would preclude the completion of the DMR procedure, including tortuous anatomy\n    4. Malignancy newly diagnosed by endoscopy\n    5. Upper GI conditions (esophageal, gastric, or intestinal) such as clinically significant ulcers, polyps, varices, strictures, congenital or acquired intestinal telangiectasia, or other conditions listed under exclusion criteria\n45. Unwilling or unable to comply with study visits and other study procedures as required per protocol\n46. Recovered from severe COVID-19 infection (requiring hospitalization) but with persistent long COVID-19 symptoms (i.e., the individual has not recovered for several weeks or months since the start of symptoms that were suggestive of COVID-19, irrespective if the individual was tested or not)",
        "InclusionCriteria": "Subjects must meet all of the following criteria for inclusion in the study:\n\n1. Males and non-pregnant non-lactating females\n2. Age between 21 and 70 years (both inclusive)\n3. Subjects on at least one glucose lowering agent (GLA) with no changes in GLA medications or dosing for at least 12 weeks prior to the screening visit\n\n   Permitted GLAs include:\n   * Metformin,\n   * GLP-1 RA including dual peptide agonists and related molecules (e.g., GLP-1/GIP RA),\n   * DPP-4i,\n   * TZDs,\n   * SGLT2is,\n   * SUs,\n   * Meglitinides,\n   * Insulin (basal or basal combined with short-acting), up to a total of 100 units daily\n4. HbA1c of 7.5%-10% (both inclusive)\n5. BMI \\>24 to \u226440 kg/m2\n6. WOCBP should have a negative urine beta hCG pregnancy test and must agree to use two of the established contraceptive methods throughout the study duration\n7. Able to sign an ICF and comply with study requirements",
        "ExclusionCriteria": "45. Unwilling or unable to comply with study visits and other study procedures as required per protocol\n46. Recovered from severe COVID-19 infection (requiring hospitalization) but with persistent long COVID-19 symptoms (i.e., the individual has not recovered for several weeks or months since the start of symptoms that were suggestive of COVID-19, irrespective if the individual was tested or not)",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "21 Years",
        "NCTId": "NCT04419779",
        "startDate": "2021-03-08",
        "completionDate": "2026-01",
        "durationDays": 1760,
        "daysUntilEnd": 510
    },
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n1. Obese youth 11-18 years of age with T1D at time of enrollment.\n2. Lean youth 11-18 years of age with T1D at time of enrollment.\n\nExclusion Criteria:\n\n1. Known monogenic forms of diabetes or Type 2 diabetes (confirmed clinically and by genetic/antibody testing).\n2. History of ongoing infection or antibiotic treatment within the past month;\n3. History of immune-compromise, recurrent infections, steroid intake (inhaled or oral forms) or other immunosuppressant use in the past 6 months.\n4. History of chronic gastrointestinal disease, possible or confirmed celiac disease;\n5. Participation in any research intervention trials within the past 3 months.\n6. History of treatment or use of metformin, a type 2 diabetes medication.",
        "InclusionCriteria": "1. Obese youth 11-18 years of age with T1D at time of enrollment.\n2. Lean youth 11-18 years of age with T1D at time of enrollment.",
        "ExclusionCriteria": "1. Known monogenic forms of diabetes or Type 2 diabetes (confirmed clinically and by genetic/antibody testing).\n2. History of ongoing infection or antibiotic treatment within the past month;\n3. History of immune-compromise, recurrent infections, steroid intake (inhaled or oral forms) or other immunosuppressant use in the past 6 months.\n4. History of chronic gastrointestinal disease, possible or confirmed celiac disease;\n5. Participation in any research intervention trials within the past 3 months.\n6. History of treatment or use of metformin, a type 2 diabetes medication.",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "11 Years",
        "NCTId": "NCT05414409",
        "startDate": "2022-09-28",
        "completionDate": "2026-08-01",
        "durationDays": 1403,
        "daysUntilEnd": 722
    },
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n* Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study.\n* Ability to sign informed consent/assent (as applicable for children).\n\nExclusion Criteria:\n\n* Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or\n* Inability to comply with the study visit schedule and required assessments.",
        "InclusionCriteria": "* Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study.\n* Ability to sign informed consent/assent (as applicable for children).",
        "ExclusionCriteria": "* Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or\n* Inability to comply with the study visit schedule and required assessments.",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "8 Years",
        "NCTId": "NCT02734277",
        "startDate": "2016-08-18",
        "completionDate": "2025-03",
        "durationDays": 3117,
        "daysUntilEnd": 204
    },
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of acute pancreatitis (AP) 0-90 days prior to enrollment\n* Participant fully understands and is able to participate in all aspects of the study, including providing informed consent, completion of case report forms, telephone interviews, metabolic testing, and planned longitudinal follow-ups\n\nExclusion Criteria:\n\n* Diagnosis of definite chronic pancreatitis (CP) at enrollment (see also study definitions) based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic Resonance Imaging (MRI) or Magnetic Resonance Cholangiopancreatography (MRCP): (a) Parenchymal or ductal calcifications on CT scan (after excluding the possibility that calcifications are vascular); (b) Intraductal filling defects suggestive of calcifications on MRI and/or MRCP\n* Potential participants with post-endoscopic retrograde cholangiopancreatography (ERCP) AP who are hospitalized for \\<48 hours.\n* Prior (i.e., before enrollment) direct endoscopic necrosectomy of the pancreas or percutaneous necrosectomy or drainage of necrotic collection(s). Participants who require this during follow-up will remain in the study\n* Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and metastasis\n* Confirmed or suspected cystic tumor associated with main pancreatic duct dilation, or believed to be the cause of AP (in the site-PI's judgement).\n* Prior pancreatic surgery, including, but not limited to: distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, Frey procedure.\n* Use of disallowed concomitant medications within 30 days prior to enrollment. A comprehensive list of disallowed medications will be included and routinely updated in the study's Manual of Procedures\n* Severe systemic illness that in the judgement of the investigative team will confound outcome assessments of diabetes mellitus and immunological outcomes or pose additional risk for harms, including: history of solid organ transplant, acquired immunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanoma skin cancer) within 12 months prior to enrollment, chronic kidney disease with estimated glomerular filtration rate (eGFR) \\< 30 or on dialysis prior to AP, and decompensated cirrhosis (based on imaging or biopsy), or any other medical condition that in the opinion of the site-PI carries a life expectancy of \\<12 months\n* Known pregnancy at the time of enrollment. Participants who become pregnant during follow-up will remain in the study, but may have modified study assessments for safety as detailed in the Manual of Procedures\n* Incarceration\n* Any other condition or factor that would compromise the participant's safety or the scientific integrity of the study",
        "InclusionCriteria": "* Diagnosis of acute pancreatitis (AP) 0-90 days prior to enrollment\n* Participant fully understands and is able to participate in all aspects of the study, including providing informed consent, completion of case report forms, telephone interviews, metabolic testing, and planned longitudinal follow-ups",
        "ExclusionCriteria": "* Diagnosis of definite chronic pancreatitis (CP) at enrollment (see also study definitions) based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic Resonance Imaging (MRI) or Magnetic Resonance Cholangiopancreatography (MRCP): (a) Parenchymal or ductal calcifications on CT scan (after excluding the possibility that calcifications are vascular); (b) Intraductal filling defects suggestive of calcifications on MRI and/or MRCP\n* Potential participants with post-endoscopic retrograde cholangiopancreatography (ERCP) AP who are hospitalized for \\<48 hours.\n* Prior (i.e., before enrollment) direct endoscopic necrosectomy of the pancreas or percutaneous necrosectomy or drainage of necrotic collection(s). Participants who require this during follow-up will remain in the study\n* Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and metastasis\n* Confirmed or suspected cystic tumor associated with main pancreatic duct dilation, or believed to be the cause of AP (in the site-PI's judgement).\n* Prior pancreatic surgery, including, but not limited to: distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, Frey procedure.\n* Use of disallowed concomitant medications within 30 days prior to enrollment. A comprehensive list of disallowed medications will be included and routinely updated in the study's Manual of Procedures\n* Severe systemic illness that in the judgement of the investigative team will confound outcome assessments of diabetes mellitus and immunological outcomes or pose additional risk for harms, including: history of solid organ transplant, acquired immunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanoma skin cancer) within 12 months prior to enrollment, chronic kidney disease with estimated glomerular filtration rate (eGFR) \\< 30 or on dialysis prior to AP, and decompensated cirrhosis (based on imaging or biopsy), or any other medical condition that in the opinion of the site-PI carries a life expectancy of \\<12 months\n* Known pregnancy at the time of enrollment. Participants who become pregnant during follow-up will remain in the study, but may have modified study assessments for safety as detailed in the Manual of Procedures\n* Incarceration\n* Any other condition or factor that would compromise the participant's safety or the scientific integrity of the study",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "18 Years",
        "NCTId": "NCT06401577",
        "startDate": "2024-09-01",
        "completionDate": "2027-03-31",
        "durationDays": 941,
        "daysUntilEnd": 964
    }
]